BioSpace News Archive

Stryker (NYSE:SYK) announced today that its Board of Directors intends to nominate Rachel Ruggeri for election to the Company’s Board of Directors at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer.

Sosei Group Corporation announces that PIVLAZ™ 150 mg has received marketing approval from the Ministry of Food and Drug Safety in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing.

Faron Pharmaceuticals Ltd. announces the publication of the full safety and anti-tumor efficacy results from the first-in-human Phase 1/2 MATINS trial of bexmarilimab in patients with treatment-refractory late-stage solid tumors in Cell Reports Medicine.

AlzeCure Pharma AB announced that the company is participating at Redeye Investor Forum in Göteborg on December 14 at 18:50 CET, where CEO Martin Jönsson will present and answer questions about the latest developments and the company’s plans going forward.

SpyBiotech announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus using its Hepatitis B virus-like-particle platform technology.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including Advanced Therapy Medicinal Products, announced that Gunnar Voss von Dahlen has been appointed as Chief Financial Officer, effective December 1, 2023.

Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, announced a new publication in the Journal of Clinical Neuroscience.

Visgenx, Inc announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories International, Inc., for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD).

Merck (NYSE: MRK) today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, with or without docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy.